<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04098861</url>
  </required_header>
  <id_info>
    <org_study_id>FF-2019-058</org_study_id>
    <nct_id>NCT04098861</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Latanoprost/Timolol for Primary Open Angle Glaucoma</brief_title>
  <official_title>Efficacy and Safety of Latanoprost/Timolol Fixed Combination Dosed Twice Daily Compared to Once Daily in Patients With Primary Open Angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universiti Kebangsaan Malaysia Medical Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universiti Kebangsaan Malaysia Medical Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intraocular pressure (IOP) is the most important modifiable risk factor to prevent and delay
      progression of glaucoma. IOP reduction has been proven to delay the onset and progression of
      glaucoma, and uncontrolled IOP is constantly associated with progression of visual field
      loss.

      Medical therapy is the first line in IOP reduction for Primary Open Angle Glaucoma (POAG). It
      is a known fact that glaucoma patients often require addition of a second antiglaucoma
      medications when disease progresses or tachyphylaxis occurs. It was reported that more than
      50% of patients require 2 or more medications to achieve optimum IOP control.

      Nevertheless, compliance and adherence are often impaired with multiple-drug therapy.
      Combining two ocular hypotensive agents in one bottle may help patients adhere to therapeutic
      regimen by reducing the number of medications used and the total number of doses
      administered.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>A single-center, randomized open-labeled, prospective, crossover study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Intraocular pressure reduction</measure>
    <time_frame>4 weeks</time_frame>
    <description>IOP reduction with LTFC given once and twice daily in POAG patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: Side effects</measure>
    <time_frame>4 weeks</time_frame>
    <description>Side effects of LTFC given twice daily in POAG patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>once daily group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Latanoprost/Timolol Fixed Combination (LTFC) will be administered once daily for 4 weeks. The IOP will be determined on Day 14 and 28. The following examinations will be performed: evaluation of conjunctiva hyperemia, anterior chamber reaction, applanation tonometry, measurement of blood pressure and heart rate.
For once daily dosing, the eye drops will be instilled at 8am every morning. The IOP will be taken at 9am-12pm on study day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>twice daily group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Latanoprost/Timolol Fixed Combination (LTFC) will be administered twice daily for 4 weeks. The IOP will be determined on Day 14 and 28. The following examinations will be performed: evaluation of conjunctiva hyperemia, anterior chamber reaction, applanation tonometry, measurement of blood pressure and heart rate.
For twice dosing, the eye drops will be instilled at 8am and 8pm. The IOP will be taken at 9am-12pm on study day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latanoprost/Timolol</intervention_name>
    <description>Latanoprost/Timolol Fixed Combination</description>
    <arm_group_label>once daily group</arm_group_label>
    <arm_group_label>twice daily group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 and above

          2. Able to provide informed consent

          3. Diagnosed as having unilateral or bilateral, mild to moderate POAG

          4. The POAG treated with only two antiglaucoma

        Exclusion Criteria:

          1. Advanced POAG

          2. Patient with contraindication for topical use of a-blocker and prostaglandin analogue

          3. Patient with contraindication for systemic use of a-blocker

          4. Patient on systemic use of a-blocker such as metoprolol, propranolol, atenolol

          5. History of orbital or ocular trauma.

          6. History of cataract surgery less than 6 months.

          7. History of previous ocular surgery; e.g. vitreoretinal surgery, corneal
             transplantation or glaucoma surgery

          8. Any active eye infections or corneal ulceration.

          9. Patient with ocular surface disease

         10. Other ocular disease that might interfere with IOP measurements or result

         11. Precious eye i.e patient with only one good eye

         12. Contact lens is not allowed within 1 week before the start of study and during the
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>gender identity</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mohd Hairul Nizam Harun, MSc</last_name>
    <phone>+0391457447</phone>
    <email>hairulnizam@ppukm.ukm.edu.my</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universiti Kebangsaan Malaysia Medical Centre</name>
      <address>
        <city>Cheras</city>
        <state>Wilayah Persekutuan Kuala Lumpur</state>
        <zip>56000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohd Hairul</last_name>
      <phone>192347377</phone>
      <email>hairulnizam@ppukm.ukm.edu.my</email>
    </contact>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 19, 2019</study_first_submitted>
  <study_first_submitted_qc>September 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2019</study_first_posted>
  <last_update_submitted>September 19, 2019</last_update_submitted>
  <last_update_submitted_qc>September 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universiti Kebangsaan Malaysia Medical Centre</investigator_affiliation>
    <investigator_full_name>Norshamsiah Md Din</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

